The following are highlights of several trials sponsored by Georgia CORE. For a comprehensive listing of clinical trials in Georgia, please visit www.georgiacancertrials.org.
Active CORE Research Sites by Study
|
EU822-03 |
ABX 018 |
GOG |
Pfizer A7471028 |
|
Augusta Oncology Associates |
• |
|
|
|
|
Central Georgia Cancer Care |
• |
|
|
|
|
DeKalb Medical |
• |
• |
|
• |
|
Georgia Cancer Center for Excellence at Grady |
• |
• |
• |
• |
|
Georgia Cancer Specialists |
• |
• |
|
|
|
John. B. Amos Cancer Center |
• |
|
• |
• |
|
Medical College of Georgia Cancer Center |
|
|
• |
|
|
Memorial Health University Medical Center |
|
|
• |
|
|
Northeast Georgia Cancer Care |
|
• |
|
|
|
Northwest Georgia Oncology Centers |
• |
|
|
|
|
Peachtree Hematology Oncology Consultants |
|
• |
|
|
|
Piedmont Hospital |
|
• |
|
|
|
Wellstar Health System |
• |
|
|
|
|
Winship Cancer Institute of Emory University |
• |
|
• |
• |
EU822-03 - Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine as Induction Therapy for Early Stage Breast Cancer (Closed to Accrual)
ABX 018 - NeoAdjuvant Trial of Trastuzumab in Combination with Dose-Dense ABI007 (Abraxane) followed by Vinorelbine for HER2 Overexpressing Early Stage Breast Cancer
Pfizer A7471028 - Randomized Phase 2 Trial of PF-00299804 Versus Erlotinib For The Treatment Of Advanced Non-Small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen (Closed to Accrual)
GOG (Gynecologic Oncology Group)
If you have questions about trials sponsored by Georgia CORE, please contact Georgia CORE’s Research Director, Diane Hicklin-Coleman, at dhicklin@georgiacore.org or 404-588-4082.
|